Liposomal doxorubicin (Doxil®)

Porche, Demetrius J.

doi:10.1016/s1055-3290(96)80016-1

Cited by 26 publications

(13 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The low production cost, flexibility to carry drugs with various physical chemical properties, low immunogenicity and apparent enhanced drug delivery efficiencies have made liposomes a popular drug delivery carrier. The marketed liposomal drugs, doxorubicin (DOXIL) [17] and daunorubicin (DaunoXome), have also addressed the serious side effects in the form of dose-limiting cardiotoxicity. Further, the specificity of drug delivery can be increased by coating drug-loaded liposomes with ligands targeting specific cell surface markers, like transferrin receptor (TfR), whose expression is increased in CML cells.…”

Section: Introductionmentioning

confidence: 99%

Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis

et al. 2016

View full text Add to dashboard Cite

The abundance of the BCR/ABL protein critically contributes to CML pathogenesis and drug resistance. However, understanding of molecular mechanisms underlying BCR/ABL gene regulation remains incomplete. While BCR/ABL kinase inhibitors have shown unprecedented efficacy in the clinic, most patients relapse. In this study, we demonstrated that the Sp1 oncogene functions as a positive regulator for BCR/ABL expression. Inactivation of Sp1 by genetic and pharmacological approaches abrogated BCR/ABL expression, leading to suppression of BCR/ABL kinase signaling and CML cell proliferation. Because of potential adverse side effects of bortezomib (BORT) in imatinib-refractory CML patients, we designed a transferrin (Tf)-targeted liposomal formulation (Tf-L-BORT) for BORT delivery. Cellular uptake assays showed that BORT was efficiently delivered into K562 cells, with the highest efficacy obtained in Tf-targeted group. After administered into mice, L-BORT exhibited slower clearance with less toxicity compared to free BORT. Furthermore, L-BORT exposure significantly blocked BCR/ABL kinase activities and sensitized CML cell lines, tumor cells and doxorubicin (DOX) resistant cells to DOX. This occurred through the more pronounced inhibition of BCR/ABL activity by L-BORT and DOX. Collectively, these findings highlight the therapeutic relevance of disrupting BCR/ABL protein expression and strongly support the utilization of L-BORT alone or in combination with DOX to treat CML patients with overexpressing BCR/ABL.

show abstract

Section: Introductionmentioning

confidence: 99%

Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Over the past 25 years, conventional phospholipid-based liposomes have been utilized for a variety of biomedical applications ranging from targeted drug delivery [ 9 ], diagnostic imaging [ 10 ], gene therapy [ 11 ] to biosensors [ 12 ]. Structural dynamics of the bilayers that constitute liposomal vesicles has been well studied and today, a number of commercially available liposomes are readily used in healthcare applications [ 13 , 14 ]. Liposomes that mimic biological membranes are typically comprised of glycerol-based phospholipids which contain a hydrophilic/polar head-group and one or two hydrophobic/nonpolar hydrocarbon chains of varying length [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Self assembly of amphiphilic C60 fullerene derivatives into nanoscale supramolecular structures

et al. 2007

View full text Add to dashboard Cite

Background: The amphiphilic fullerene monomer (AF-1) consists of a "buckyball" cage to which a Newkome-like dendrimer unit and five lipophilic C 12 chains positioned octahedrally to the dendrimer unit are attached. In this study, we report a novel fullerene-based liposome termed 'buckysome' that is water soluble and forms stable spherical nanometer sized vesicles. Cryogenic electron microscopy (Cryo-EM), transmission electron microscopy (TEM), and dynamic light scattering (DLS) studies were used to characterize the different supra-molecular structures readily formed from the fullerene monomers under varying pH, aqueous solvents, and preparative conditions.

show abstract

“…Many nanoparticles are being developed as cancer therapeutic and diagnostic agents. There are several approved drugs in nanoparticle formulations including Doxil [84–86], DepoCyt [87], and Estrasorb [88]. For example, Doxil is a liposome formulation of doxorubicin functionalized with PEG [84–86].…”

Section: E Peptide-particle and Peptide-polymer Conjugatesmentioning

confidence: 99%

Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases

Moral

Siahaan

2018

CTMC

View full text Add to dashboard Cite

Overexpressed cell-surface receptors are hallmarks of many disease states and are often used as markers for targeting diseased cells over healthy counterparts. Cell adhesion peptides, which are often derived from interacting regions of these receptor-ligand proteins, mimic surfaces of intact proteins and, thus, have been studied as targeting agents for various payloads to certain cell targets for cancers and autoimmune diseases. Because many cytotoxic agents in the free form are often harmful to healthy cells, the use of cell adhesion peptides in targeting their delivery to diseased cells has been studied to potentially reduce required effective doses and associated harmful side-effects. In this review, multiple cell adhesion peptides from extracellular matrix and ICAM proteins were used to selectively direct drug payloads, signal-inhibitor peptides, and diagnostic molecules, to diseased cells over normal counterparts. RGD constructs have been used to improve the selectivity and efficacy of diagnostic and drug-peptide conjugates against cancer cells. From this precedent, novel conjugates of antigenic and cell adhesion peptides, called bifunctional peptide inhibitors (BPIs), have been designed to selectively regulate immune cells and suppress harmful inflammatory responses in autoimmune diseases. Similar peptide conjugations with imaging agents have delivered promising diagnostic methods in animal models of rheumatoid arthritis. BPIs have also been shown to generate immune tolerance and suppress autoimmune diseases in animal models of type-1 diabetes, rheumatoid arthritis, and multiple sclerosis. Collectively, these studies show the potential of cell adhesion peptides in improving the delivery of drugs and diagnostic agents to diseased cells in clinical settings.

show abstract

Liposomal doxorubicin (Doxil®)

Cited by 26 publications

References 3 publications

Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis

Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis

Self assembly of amphiphilic C60 fullerene derivatives into nanoscale supramolecular structures

Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases

Contact Info

Product

Resources

About